<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Elevance Health's operating expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        3/30/2025 08:18pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Elevance Health's operating expenses in Q4 2024 are not currently available. However, based on the information available, we can infer that the company's focus on cost-cutting strategies and operational efficiencies suggests that any increases in operating expenses were likely managed effectively.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au){return {layout:"default",data:[{noData:c,currentQuestion:e,textDescription:I,comeFrom:"AInvestShareLink",events:[],answerSource:i}],fetch:{},error:j,state:{sharePreviewModule:{loadJgySuccess:g,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:i,cache_builder:a,reply_action:"Answer",execute_mode:A,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Elevance Health's operating expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Elevance Health's operating expenses trend in Q4 2024?\",\"user_id\":\"dp95989424\",\"user_name\":\"\",\"trace_id\":\"091ea499-afa3-4c81-b55c-1e701eb57f4c\",\"session_id\":\"091ea499-afa3-4c81-b55c-1e701eb57f4c\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:J,raw_data:{number:K,title:L,summary:M,full_summary:"Elevance Health Reports Third Quarter 2024 Results 3Q 2024 operating revenue of $44.7 billion 3Q 2024 adjusted operating gain1 of $2.4 billion 3Q 2024 diluted EPS2 of $4.36; adjusted diluted EPS1 of $8.37 4Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE: ELV) reported third quarter 2024 results. “We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business. We expect Medicaid rates will align with the needs of our members in time, and are taking proactive actions to enhance operational efficiencies that will ensure we emerge from this period even stronger.” Gail K. Boudreaux President and Chief Executive Officer Given third quarter results and the timing mismatch between Medicaid rates and acuity, Elevance Health now expects 2024 GAAP net income per diluted share to be approximately $26.50 and adjusted net income per diluted share to be approximately $33.00. 1. Refer to GAAP reconciliation tables herein for reconciliation of GAAP to adjusted measures.  2. Earnings per diluted share (\"EPS\").      Elevance Health   Consolidated Enterprise Highlights   (Unaudited)     (In billions) Three Months Ended   September 30, 2024 September 30, 2023 June 30, 2024     Operating Revenue1 $44.7 $42.5 $43.2   Operating Gain1,2 $1.4 $1.8 $2.8   Adjusted Operating Gain1,3 $2.4 $2.5 $2.8     Operating Margin1 3.1 % 4.1 % 6.4 %   Adjusted Operating Margin1,3 5.3 % 6.0 % 6.6 %     1. See “Basis of Presentation” herein.  2. Operating Gain for the three months ended September 30, 2024, and September 30, 2023, include items that are excluded from adjusted shareholders' net income. See \"GAAP Reconciliation.\"  3. Adjusted Operating Gain for the three months ended September 30, 2024, and September 30, 2023, exclude items that are excluded from adjusted shareholders' net income. See \"GAAP Reconciliation\" herein.   Operating revenue was",url:N,image_url:a,video_url:a,publish_time:s,search_extra_info:{search_burial_info:{id:O,uid:B,ab:{scene_id:t,layer_exp:[{layer_id:u,exp_id:v}]}}},simhash:"85ad07e34a01f361",msg_id:B}},{info_type:J,raw_data:{number:P,title:Q,summary:R,full_summary:"Elevance Health (NYSE:ELV) is showing steady progress with its Q3 2024 results, pulling in $44.7 billion in operating revenue, up 5.3% from last year. Despite facing headwinds in Medicaid, the company continues to manage costs well, keeping its adjusted operating gain strong at $2.4 billion. However, challenges from Medicaid membership losses led to a 19.8% dip in operating gain to $1.4 billion. These results reflect both the complexity of the current healthcare landscape and Elevance's ability to adapt with focused cost-cutting strategies. Warning! GuruFocus has detected 5 Warning Sign with GS. The Health Benefits segment saw a modest 4.2% boost in revenue to $38.3 billion but took a hit in operating gain, which dropped by 12.5% to $1.6 billion. The decline came from the fallout of Medicaid redeterminations, trimming its membership and pushing margins down. On the other hand, Carelon, which includes pharmacy and care services, surged ahead with a 15% revenue jump to $13.8 billion, and a 20% rise in operating gain to $0.8 billion, buoyed by strong demand for its products and the integration of Paragon Healthcare. Looking ahead, Elevance remains confident, declaring a $1.63 per share dividend for Q4 2024 and executing a $60 million share buyback. The company is expecting full-year GAAP net income per share of $26.50 and adjusted net income of $33.00. Despite ongoing Medicaid challenges, Elevance is positioning itself to capitalize on efficiencies and emerge stronger, making it clear that they're in for the long haul. This article first appeared on GuruFocus.",url:S,image_url:a,video_url:a,publish_time:s,search_extra_info:{search_burial_info:{id:T,uid:C,ab:{scene_id:t,layer_exp:[{layer_id:u,exp_id:v}]}}},simhash:"94d75d95ef710066",msg_id:C}}],answer_chain_name:U,native_answer:a,come_from:a,text_answer:I,trace_id:f,cost:10122,event_names:a,question:e,fallback_type:V,input_type:W,fall_back_reason:{fall_back_type:V,risk_detail:{matched_words:[]}},session_id:f,first_return_cost:2538,cache_type:a,question_id:f,transfer_question:e,signal_type:"ON_COMPLETE",start_time:X,remote_svc:i,slots:[],answer_type:A,user_id:w,skill_name:D},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:f,session_id:f,user_id:w,question:e,source:i,raw_question:e,version:"3.4.1",action_name:D,nlu:{entity:[{type:Y,value:"ELV.N",market:Z}]},deep_research:c,deep_thinking:c,agent_mode:"normal_agent"},extra:{}},{answer_path:k,section:{id:l,info_texts:["Thinking"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:k,section:{id:l,info_texts:["Querying Stock: ELV Operating Expenses in Q4 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:_},logs:[],extra:{action:"Querying Stock",action_input:"ELV Operating Expenses in Q4 2024",thought:"The user seeks to analyze Elevance Health's (ELV) operating expenses in Q4 2024. I should focus on ELV's Q4 2024 operating expenses data. I will use FinQuery for the data mentioned above."}},{answer_path:d,section:{id:E,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Searching Web: Elevance Health Operating Expenses Q4 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:_},logs:[],extra:{action:"Searching Web",action_input:"Elevance Health Operating Expenses Q4 2024",thought:"I am unable to obtain ELV's Q4 2024 operating expenses using FinQuery, now I will try again using Search."}},{answer_path:d,section:{id:E,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:E,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Generating Answer"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:y,info_texts:[],show_type:n,voice_txt:"E",text_answer:$,rich_text:$,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:aa,info_texts:[],show_type:n,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:N,image_url:a,video_url:a,title:L,summary:M,index:K,publish_time:s,search_id:O,search_uid:B,search_ab:{scene_id:t,layer_exp:[{layer_id:u,exp_id:v}]},jump_type:ab}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:y,info_texts:[],show_type:n,voice_txt:a,text_answer:ac,rich_text:ac,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:aa,info_texts:[],show_type:n,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:S,image_url:a,video_url:a,title:Q,summary:R,index:P,publish_time:s,search_id:T,search_uid:C,search_ab:{scene_id:t,layer_exp:[{layer_id:u,exp_id:v}]},jump_type:ab}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:y,info_texts:[],show_type:n,voice_txt:F,text_answer:F,rich_text:F,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"ELV",market_id:Z,name:ad,domain:Y},pos:g,section_id:y,txt:ad,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Completed"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:o,query_text:o,trace_info:{item_id:"0dc1a86d074aa3c1d2feb62bb1388182",item_type:h,item_name:o,rec_info:ae}},{display_text:p,query_text:p,trace_info:{item_id:"f7393e9642d19b50e0127ef38faa0380",item_type:h,item_name:p,rec_info:af}},{display_text:q,query_text:q,trace_info:{item_id:"9d43c481331a27bb7e7e0195647bed19",item_type:h,item_name:q,rec_info:ag}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:g,type:"1",display2:c,url:a}},request_config:[{source_type:ah,related_name:ai}],puuid:G,tag:a,category:"custom",uuid:aj}],global:{urp_static_data:[{name:ai,value:{status_code:g,columns:[{type:r,index_name:ak,key:ak},{type:r,index_name:al,key:al},{type:r,index_name:am,key:am},{type:r,index_name:an,key:an},{type:r,index_name:ao,key:ao}],datas:[{send_text:o,item_type:h,rec_info:ae,display_text:o,rec_reason:a},{send_text:p,item_type:h,rec_info:af,display_text:p,rec_reason:a},{send_text:q,item_type:h,rec_info:ag,display_text:q,rec_reason:a}],dataSize:ah,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ap,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:z,"min-height":"100%",position:aq,height:z},isMaterial:c,id:ap,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:g,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:H,componentUuid:aj,script:[{name:ar,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:H,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:H},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:z,position:aq,height:z},isMaterial:b,_id:19,id:ar,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:as,voice_txt:a,tracking_info:{},uuid:G},order:{is_auto:c,render_for:as,chart_type:"command",puuid:G}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:D,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:A,answer_chain_name:U},is_deep_research:c,deep_thinking:c,create_time:1743337124609},is_last:b}],questionItem:{data:{qStr:e,encodeFlag:c,imageData:j,docsData:[],quoteData:j},tplType:"question"},events:at,agentId:a,param:{entity_info:{},add_info:{ori_question:e},event_list:at,client_ip:a,question:e,user_id:w,user_name:a,trace_id:f,session_id:f,source:i,input_type:W}}],userId:w,userName:a,startTime:X,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:j,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:g,traceTableData:j,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Felevance-healths-operating-expenses-trend-q4-2024-974630\u002F",config:{_app:{basePath:au,assetsPath:au,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer","How did Elevance Health's operating expenses trend in Q4 2024?","091ea499-afa3-4c81-b55c-1e701eb57f4c",0,"llm_generated","ths_ainvest_lite_web",null,"progress\u002Fsearching_for",1000,"searching_for","rich_text","💲 What was Elevance Health's total operating expense in Q4 2024?","⚖️ What was the year-over-year change in Elevance Health's operating expenses in Q4 2024?","📊 What was the operating margin percentage for Elevance Health in Q4 2024?","STR","2024-10-17","oeqxkhszf","oeqxkhszf_layer","base","dp95989424","signal",2001,"auto","agent","f07e1fa63e7e5723","402be9205b0aaac6","review stocks",999,".","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Elevance Health's operating expenses in Q4 2024 are not currently available. However, based on the information available, we can infer that the company's focus on cost-cutting strategies and operational efficiencies suggests that any increases in operating expenses were likely managed effectively.","search",2,"Elevance Health Reports Third Quarter 2024 Results","Elevance Health  Consolidated Statements of Income  (Unaudited)  (In millions, except per share data) Three Months Ended September 30 Nine Months Ended September 30   2024 2023 Change 2024 2023 Change    Revenues  Premiums $ 36,809 $ 35,259 4.4 % $ 107,921 $ 107,716 0.2 %  Product revenue 5,887 5,17...","https:\u002F\u002Fwww.morningstar.com\u002Fnews\u002Fbusiness-wire\u002F20241016900631\u002Felevance-health-reports-third-quarter-2024-results","f07e1fa63e7e5723_5",4,"Elevance Health Reports Strong Q3 2024 Results Amid Medicaid Challenges","Elevance Health (NYSE:ELV) is showing steady progress with its Q3 2024 results, pulling in $44.7 billion in operating revenue, up 5.3% from last year. Despite facing headwinds in Medicaid, the company continues to manage costs well, keeping its adjusted operating gain strong at $2.4 billion. However...","https:\u002F\u002Ffinance.yahoo.com\u002Fnews\u002Felevance-health-reports-strong-q3-145144691.html","402be9205b0aaac6_0","agent_common_v2\nagent-summary","NONE","typewrite",1743337114487,"stock","169","thinking","Elevance Health's operating expenses in Q4 2024 are not currently available. However, based on the information available, we can infer that the company's focus on cost-cutting strategies and operational efficiencies suggests that any increases in operating expenses were likely managed effectively[^2]",2000,"normal","[^4]","Elevance Health","2+698_496_21_554+0+0+091ea499-afa3-4c81-b55c-1e701eb57f4c+0dc1a86d074aa3c1d2feb62bb1388182+llm_generated+aimeTagAnalysis+0+0.04794193059206009+1","2+698_496_21_554+0+0+091ea499-afa3-4c81-b55c-1e701eb57f4c+f7393e9642d19b50e0127ef38faa0380+llm_generated+aimeTagAnalysis+0+0.036954306066036224+2","2+698_496_21_554+0+0+091ea499-afa3-4c81-b55c-1e701eb57f4c+9d43c481331a27bb7e7e0195647bed19+llm_generated+aimeTagAnalysis+0+0.03611314296722412+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>